Absci (NASDAQ:ABSI) Shares Up 14.6% – Should You Buy?

Shares of Absci Corporation (NASDAQ:ABSI – Get Free Report) rose 14.6% during mid-day trading on Wednesday. The company traded as high as $8.25 and last traded at $8.6890. Approximately 690,408 shares were traded during trading, a decline of 84% from the average daily volume of 4,321,190 shares. The stock had previously closed at $7.58.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. BTIG Research reissued a “buy” rating and set a $16.00 price target on shares of Absci in a research report on Thursday, November 12th. Needham & Company LLC lifted their price objective on Absci from $11.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 12th. Lifesci Capital started coverage on shares of Absci in a report on Wednesday, September 9th. They issued an “outperform” rating on the stock. Jefferies Financial Group initiated coverage on shares of Absci in a research report on Thursday, October 29th. They set a “buy” rating and a $14.00 price target for the company. Finally, JPMorgan Chase & Co. raised their target price on shares of Absci from $14.00 to $15.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.90.

Get Our Latest Stock Report on Absci

Absci Price Performance

The business’s 50 day simple moving average is $9.59 and its 200 day simple moving average is $6.91. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -10.33 and a beta of 2.22.

Absci (NASDAQ:ABSI – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). Absci had a negative return on equity of 61.60% and a negative net margin of 8,451.31%. The company had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.66 million. As a group, analysts expect that Absci Corporation will post -0.76 EPS for the current fiscal year.

Institutional Investors Weigh In On Absci

Large investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Absci in the 2nd quarter valued at approximately $141,112,000. Marshall Wace LLP grew its position in Absci by 287.3% in the third quarter. Marshall Wace LLP now owns 1,945,901 shares of the company’s stock valued at $20,957,000 after purchasing an additional 1,443,494 shares in the last quarter. Siren L.L.C. acquired a new stake in shares of Absci in the first quarter valued at approximately $5,400,000. Integral Health Asset Management LLC grew its stake in shares of Absci by 62.5% in the third quarter. Integral Health Asset Management LLC now owns 1,300,000 shares of the company’s stock valued at $14,001,000 after acquiring an additional 500,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC bought a new stake in Absci during the second quarter worth $10,366,000. Institutional investors and hedge funds own 52.05% of the company’s stock.

About Absci

(Get Free Report)

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.

See Also

Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.